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Tankyrase inhibition aggravates kidney injury in the
absence of CD2AP
S Kuusela*,1, H Wang1, AA Wasik1, H Suleiman2 and S Lehtonen1
Inappropriate activation of the Wnt/β-catenin pathway has been indicated in podocyte dysfunction and injury, and shown to
contribute to the development and progression of nephropathy. Tankyrases, multifunctional poly(ADP-ribose) polymerase (PARP)
superfamily members with features of both signaling and cytoskeletal proteins, antagonize Wnt/β-catenin signaling. We found that
tankyrases interact with CD2-associated protein (CD2AP), a protein essential for kidney ultrafiltration as CD2AP-knockout
(CD2AP− /− ) mice die of kidney failure at the age of 6–7 weeks. We further observed that tankyrase-mediated total poly-(ADP-
ribosyl)ation (PARylation), a post-translational modification implicated in kidney injury, was increased in mouse kidneys
and cultured podocytes in the absence of CD2AP. The data revealed increased activity of β-catenin, and upregulation of
lymphoid enhancer factor 1 (LEF1) (mediator of Wnt/β-catenin pathway) and fibronectin (downstream target of Wnt/β-catenin) in
CD2AP− /− podocytes. Total PARylation and active β-catenin were reduced in CD2AP− /− podocytes by tankyrase inhibitor
XAV939 treatment. However, instead of ameliorating podocyte injury, XAV939 further upregulated LEF1, failed to downregulate
fibronectin and induced plasminogen activator inhibitor-1 (PAI-1) that associates with podocyte injury. In zebrafish, administration
of XAV939 to CD2AP-depleted larvae aggravated kidney injury and increased mortality. Collectively, the data reveal sustained
activation of the Wnt/β-catenin pathway in CD2AP− /− podocytes, contributing to podocyte injury. However, we observed that
inhibition of the PARylation activity of tankyrases in the absence of CD2AP was deleterious to kidney function. This indicates that
balance of the PARylation activity of tankyrases, maintained by CD2AP, is essential for normal kidney function. Furthermore, the
data reveal that careful contemplation is required when targeting Wnt/β-catenin pathway to treat proteinuric kidney diseases
associated with impaired CD2AP.
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The glomerular filtration barrier consists of fenestrated endo-
thelial cells, glomerular basement membrane and glomerular
epithelial cells or podocytes. Disruption of the filtration barrier
leads to proteinuria, which may progress to renal failure.
Podocytes are terminally differentiated cells with a large cell
body and interdigitating foot processes, which rest on the
glomerular basement membrane. Podocyte injury has been
shown to have an important role in the development of
proteinuria as the loss of function of several podocyte proteins
has been shown to lead to podocyte foot process effacement
and impaired glomerular ultrafiltration.1
Adapter proteinCD2-associated protein (CD2AP) is essential
for the maintenance of glomerular filtration.2 CD2AP was
originally characterized as an interaction partner of T-cell
adhesion molecule CD2,3 and as a protein upregulated during
mesenchyme to epithelium differentiation in the developing
kidney.4 In the glomerulus, CD2AP interacts with nephrin,5 the
key component of the slit diaphragm interconnecting the
neighboring podocyte foot processes.6 CD2AP regulates
cytoskeletal remodeling,7 apoptosis8 and vesicular trafficking.9
Tankyrases 1 and 2 are members of the poly(ADP-ribose)
(PAR) polymerase family.10,11 They catalyze poly(ADP-ribo-
syl)ation (PARylation), a post-translational modification target-
ing tankyrases themselves or their interaction partners,
subject the target proteins to ubiquitination and proteasomal
degradation,10 and thereby modulate diverse cellular pro-
cesses.12 During recent years, several new interaction
partners and functions have been characterized for tan-
kyrases;13–15 however, the possible involvement of tankyrases
in regulating podocyte function has remained unknown.
PARylation activity of tankyrases is involved in regulating the
activity of the canonical Wnt/β-catenin signaling pathway.16
When the pathway is inactive, β-catenin is phosphorylated
and targeted to degradation by the β-catenin destruction
complex. Tankyrases PARylate AXIN in the destruction
complex, stimulate its degradation, and thus enable depho-
sphorylation of β-catenin and its consequent translocation
to the nucleus where it together with T-cell factor/lymphoid
enhancer factor (TCF/LEF) family of co-activators drives
Wnt-specific transcriptional programs.17 In the adult kidney,
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Wnt/β-catenin pathway has been considered to be silent.
Inappropriate activation of the pathway has been indicated in
podocyte dysfunction and injury,18 and in many kidney
diseases such as diabetic nephropathy and adriamycin-
induced nephropathy.19–22
Here, we show that tankyrases are novel interaction
partners of CD2AP, and that CD2AP is a negative regulator
of tankyrases. We demonstrate that activation of β-catenin
accompanied by elevation of total PARylation associates with
podocyte injury in the absence of CD2AP. However, inhibition
of tankyrases in the absence of CD2AP enhances the
expression of podocyte injury markers and aggravates kidney
damage.
Results
Tankyrases 1 and 2 form a complex with CD2AP. We
performed a yeast two-hybrid screening on a rat glomerular
library to identify proteins that interact with the NH2 terminus
of CD2AP containing three SH3 domains. The screening
identified a clone that covered amino acids 1–190 of
tankyrase 2. Pull-down assays with the NH2 terminus or
individual SH3 domains of CD2AP fused with GST (Figure 1a,
Supplementary Figure S1a) confirmed the interaction
(Figure 1b). Immunoblotting revealed that the 2.SH3 domain
of CD2AP pulled down tankyrase 2 and tankyrase 1
overexpressed in HEK293T cells (Figure 1b,Supplementary
Figure S1b). Also endogenous tankyrases were pulled down
with the 2.SH3 domain of CD2AP from rat glomerular lysate
(Figure 1c). The interaction between CD2AP and tankyrase 2
was mediated by the ankyrin domains (Figure 1d). Both full-
length tankyrases and the ankyrin domains of tankyrase
2 were co-immunoprecipitated with endogenous CD2AP
(Figure 1e). Furthermore, CD2AP co-immunoprecipitated
endogenous tankyrases from mouse kidney and isolated rat
glomerular lysates (Figure 1f), confirming that CD2AP and
tankyrases form a physiological complex.
Tankyrases 1 and 2 are expressed in podocytes. Tan-
kyrases are expressed in both glomeruli and tubuli, whereas
CD2AP is found predominantly in the glomeruli (Figure 2a).
Tankyrases are also expressed in cultured wild-type (WT)
and CD2AP-knockout (CD2AP− /− ) podocytes (Figure 2b).
In kidney tankyrases localize in podocytes (Figure 2c), and in
cultured podocytes tankyrases are distributed both in the
nucleus and in the cytoplasm (Figures 2d–f) where they
partially colocalize with CD2AP (Figures 2g–i).
Figure 1 Tankyrases form a complex with CD2AP. (a) Schematic cartoon illustrating the amino acids covered by the SH3 domains and the N-terminus of CD2AP.
(b) Tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) transiently overexpressed in Hek293 cells are pulled down with GST-CD2AP, but not with GSTalone. The strongest interaction
is observed between tankyrases and the GST-2.SH3 domain of CD2AP. (c) Tankyrase 1 and tankyrase 2 endogenously expressed in rat glomeruli are pulled down with GST-2.
SH3 domain of CD2AP, but not with GSTalone. (d) The Flag-tagged ankyrin domains (Flag-ANK) of tankyrase 2 transiently overexpressed in Hek293 cells are pulled down with
GST-2.SH3 domain of CD2AP, but not with GST alone. (e) Flag-tagged tankyrase 2, tankyrase 1 and Flag-tagged ankyrin domains of tankyrase 2 co-immunoprecipitate
with CD2AP 1774 and 1764 antibodies, but not with rabbit IgG in Hek293 cells transiently transfected with Flag-tankyrase 2, tankyrase 1 or Flag-tagged ankyrin domains of
tankyrase 2. (f) Tankyrase 1 and tankyrase 2 endogenously expressed in mouse kidneys (ms kid) and rat glomeruli (rt glom) co-immunoprecipitate with CD2AP 1774 antibody, but
not with rabbit IgG. Hek293 or glomerular lysates (50 μg) are included as a control. The experiments were repeated three times with similar results
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Tankyrase-mediated total PARylation is increased in
CD2AP− /− podocytes in vitro. Immunoblotting of lysates
of WT and CD2AP− /− podocytes revealed multiple bands
for both tankyrase 1 and tankyrase 2 (Figure 3a). Tankyrase 1
is expected to migrate at 150 kDa and tankyrase 2 at
130 kDa. Quantification indicated that the total level of
tankyrase 1 is decreased but its slower migrating, modified
form is increased in CD2AP− /− podocytes compared with
WT podocytes (Figure 3b). The total level of tankyrase 2 was
similar between WT and CD2AP− /− podocytes; however,
the modified form of tankyrase 2 was increased in the
absence of CD2AP (Figure 3c).
Tankyrase 1 is modified by phosphorylation,23 and phos-
phatase (CIP) treatment of WT and CD2AP− /− cell lysates
confirmed that the slower migrating form of tankyrase 1 is
phosphorylated in podocytes (Supplementary Figure S2).
Tankyrase 1 phosphorylation can enhance its PARylation
activity23 or autoPARylation.16 We therefore examined
whether total PARylation is increased in CD2AP− /− podo-
cytes. Indeed, the absence of CD2AP increased
total PARylation in podocytes compared with WT cells
(Figure 3d). Treatment of CD2AP− /− podocytes with a
tankyrase-specific inhibitor XAV939 reduced total PARylation
(Figure 3e) whereas ABT-888 (veliparib), a PARP1 and PARP2
(poly(ADP-ribose) polymerase 1 and 2)-specific inhibitor,24,25
had no effect (Figure 3f). The effectiveness of ABT-888
was confirmed by its ability to inhibit H2O2-induced
PARP1-mediated PARylation (Supplementary Figure S3).
These data confirm that the increase in total PARylation in
the absence of CD2AP is due to the increased activity of
tankyrases.
Tankyrases typically PARylate their interaction
partners.10,13,14,16,23,26 Pull down with PAR-affinity resin from
WT podocyte lysates showed that CD2AP is not PARylated
(Figure 3g). Interestingly, we detected less PARylated
tankyrases in CD2AP− /− podocytes compared with WT
podocytes (Figures 3g and h). One of the known PARylation
targets of tankyrases is PARP1.27 PARP1 is an enzyme
involved in cell differentiation, survival and transformation, and
its main function is to repair single-stranded DNA breaks.28
Lack of CD2AP increased the PARylation of PARP1
in podocytes and tankyrase inhibitor XAV939 treatment
reduced it (Figures 3g and i), indicating that PARylation
of PARP1 in the absence of CD2AP is tankyrase mediated.
Figure 2 Tankyrases are expressed in podocytes. (a) Immunoblotting of rat glomerular and tubular fractions with antibodies that recognize tankyrases 1 and 2 (TNKS1/2) or
tankyrase 2 (TNKS2) indicates that tankyrase 1 and tankyrase 2 are expressed in both glomerular and tubular fractions. CD2AP concentrates in the glomeruli. Tubulin is included
as a control. (b) Immunoblotting indicates that tankyrases 1 and 2 are expressed in wild-type (WT) and CD2AP− /− podocyte lysates. CD2AP is detected only in the WT
podocytes as expected. Tubulin is included as a control. (c) Immunoperoxidase staining of mouse kidney section with an antibody that recognizes both tankyrases 1 and 2
(TNKS1/2) reveals that tankyrases are expressed in glomeruli, where they localize in podocytes (arrows). (d–f) Immunofluorescence staining of WT mouse podocytes shows that
tankyrases primarily localize to the perinuclear region and nucleus. DAPI labels the nuclei. (g–i) Double immunofluorescence staining shows that tankyrase 2 (g) and CD2AP (h)
partially colocalize in the perinuclear region in WT mouse podocytes (i). Scale bar: (c) 50 μm; (d–i) 20 μm
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Additionally, inhibitor treatment reduced PARylation of
tankyrases in WT and CD2AP− /− podocytes confirming
the effectiveness of the inhibitor (Figures 3g and h).
Collectively, the absence of CD2AP increases tankyrase-
mediated PARylation, and one of the PARylation targets of
tankyrases is PARP1.
Total PARylation is increased in CD2AP− /− podocytes
in vivo. Shih et al.2 showed that CD2AP-deficient mice
develop high-grade albuminuria and exhibit lesions typical of
focal segmental glomerulosclerosis (FSGS) by 3–4 weeks of
age. Kidney failure results in the death of the animals by the
age of 6–7 weeks.2,8 We examined whether we observe an
increase in total PARylation, shown to associate with kidney
injury in diabetes,29 in the kidneys of CD2AP-deficient mice at
3 weeks of age. Indeed, we observed that CD2AP deficiency
leads to increased total PARylation in the kidneys compared
with WT kidneys (Figure 4a). Double labeling of CD2AP− /−
and WT kidneys with anti-PAR and anti-WT1 antibodies
revealed that the number of podocytes with PAR-positive
Figure 3 Tankyrase-mediated total PARylation is increased in CD2AP− /− podocytes in vitro. (a) Wild-type (WT) and CD2AP− /− podocyte cell lysates were
immunoblotted with an antibody that recognizes both tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2). The expected molecular weights of tankyrase 1 and tankyrase 2 are 150
and 130 kDa, respectively. Two replicates of WTand CD2AP− /− podocyte lysates are shown. Arrowheads indicate slower migrating, modified forms and arrows indicate the
non-modified forms of tankyrases 1 and 2. The high intensity image is shown to better visualize tankyrase 2, which is expressed at a lower level than tankyrase 1 in podocytes.
Tubulin is included as a loading control. (b) Quantification of three replicate blots as in (a). The bars (white and gray parts together) indicate the total level of tankyrase 1, and the
gray part of the bar indicates the fraction of tankyrase 1 that is post-translationally modified (the upper band). Quantification indicates that tankyrase 1 is downregulated in
CD2AP− /− podocytes, but its post-translational modification is increased. (c) Quantification of three replicate blots as in (a) indicates that tankyrase 2 is expressed at a similar
level in WT and CD2AP− /− podocytes, but its post-translational modification is increased in the absence of CD2AP. (d) Total PARylation activity is increased in cultured
CD2AP− /− podocytes compared with WT podocytes. (e) Inhibition of tankyrases with a tankyrase-specific small molecule inhibitor XAV939 for 18 h (3 μM) lowers the total
PARylation in cultured CD2AP− /− podocytes. (f) Treatment of WTand CD2AP− /− podocytes with PARP1/2-specific inhibitor ABT-888 for 18 h (3μM) does not affect total
PARylation in either cell line. (g) Pull-down assay from WTand CD2AP− /− podocytes with PAR-polymer-binding-resin (WWE affinity resin) followed by western blotting with
antibodies recognizing tankyrases 1 and 2, PARP1 and CD2AP indicates that tankyrase 1 is PARylated in podocytes. PARP1 is weakly PARylated, whereas CD2AP is not
PARylated. Control pull down (control) was performed with WWE domain harboring a mutation, which renders the domain unable to bind PAR. Cell lysates (30 μg) were included
as controls. (h and i) Quantification of three replicate blots as in (g) reveals that PARylation of tankyrase 1 is reduced (h) and PARylation of PARP1 is increased (i) in CD2AP− /−
podocytes. The amounts of tankyrase 1 and PARP1 in the pull downs with WWE domain were normalized to the amounts of tankyrase 1 and PARP1 in the lysates, respectively.
Bars show the mean and error bars the ± standard error of mean (S.E.M.) of three independent experiments with three biological replicates. P-values were calculated with one-
way ANOVA (*Po0.05; **Po0.01; ***Po0.001)
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staining was significantly higher in the absence of CD2AP
(Figure 4b), and the staining for PAR was prominent in the
nuclei (Figures 4c–h,Supplementary Figure S4). CD2AP was
not PARylated in the kidney (Figure 4i). PARylation of
tankyrases was similar in WT and CD2AP− /− kidneys
(Figures 4i and j), whereas the absence of CD2AP increased
PARP1 PARylation (Figures 4i and k). Taken together, these
data are in line with the observations in cultured podocytes,
showing that the absence of CD2AP increases PARylation in
podocytes also in vivo.
Figure 4 Total PARylation is increased in CD2AP− /− podocytes in vivo. (a) Total PARylation is increased in the kidneys of CD2AP− /− mice compared with WT mice.
PARylation was measured from kidney lysates of 7 WTand 11 CD2AP− /− mice. (b) The number of PAR-positive podocytes is significantly higher in CD2AP− /− kidneys
compared with WT kidneys. Kidney sections of three wild-type and three CD2AP− /− mice were double labeled with anti-PAR and anti-WT1 IgGs. Numbers of PAR-positive
podocytes were calculated from 20 glomeruli/animal. (c–h) Representative images of WT (c–e) and CD2AP− /− (f–h) kidney sections labeled with anti-PAR (c and f) and anti-
WT1 (d and g) IgGs. Merged images (e and h) show an increase in PAR-positive podocytes (arrows) in the absence of CD2AP (h). (i) Pull-down assay fromWTand CD2AP− /−
kidney lysates with PAR-polymer-binding-resin (WWE) followed by western blotting with antibodies recognizing tankyrases 1 and 2, PARP1 and CD2AP indicates that tankyrase 1
is PARylated in mouse kidneys. PARP1 shows negligible level of PARylation in WT kidneys, but its PARylation increases in the absence of CD2AP. CD2AP is not PARylated in vivo.
(j and k) Quantification of three replicate blots as in (i) showed that there is no difference in the PARylation of tankyrase 1 (j) and that there is more PARylated PARP1 (k) in
CD2AP− /− kidneys when compared with WT. The amount of tankyrase 1 and PARP1 in the pull down with WWE domain was normalized to the amount of tankyrase 1 and
PARP1, respectively, in the lysate. Bars show the mean and error bars the ±S.E.M. of three independent experiments. P-values were calculated with one-way ANOVA (*Po0.05;
***Po0.001). Scale bar: (c–h) 25 μm
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Absence of CD2AP leads to the accumulation of active
β-catenin, Lef1 and TCF -1 in podocytes. Owing to the
observed overactivity of tankyrases, we hypothesized
that one of the mechanisms contributing to podocyte injury
in the absence of CD2AP is the activation of Wnt/β-catenin
pathway. Indeed, active β-catenin was upregulated in
CD2AP− /− podocytes compared with WT podocytes with-
out exogenous Wnt stimulation (Figure 5a), and accumulated
in the nucleus (Figures 5a–e). This was also observed in the
glomerular podocytes of CD2AP− /− mouse kidneys when
compared with WT (Figures 5f–k).
TCF/LEF family of transcription factors are the major
mediators ofWnt signaling and their expression is upregulated
by stabilized β-catenin.30 qRT-PCR indicated that the absence
of CD2AP leads to upregulation of Lef1 and TCF-1 mRNAs in
podocytes (Figure 5l), whereas TCF-3 and TCF-4 had similar
expression. Interestingly, treatment with tankyrase inhibitor,
Wnt/β-catenin pathway antagonist XAV939, had no effect
on TCF-1, TCF-3 or TCF-4 expression; however, it signifi-
cantly increased Lef1 expression in CD2AP− /− podocytes
(Figure 5l).
XAV939 inhibits tankyrases and stabilizes AXIN1, which
enhances degradation of active β-catenin.17 As expected,
XAV939 downregulated active β-catenin and increased the
levels of AXIN1 in both WT and CD2AP− /− podocytes
(Figures 6a and b). LEF1 was upregulated in CD2AP− /−
podocytes also at the protein level, and the upregulation was
further enhanced by tankyrase inhibition (Figures 6a and b).
Immunofluorescence staining confirmed that XAV939
treatment downregulates active β-catenin in both WT
and CD2AP− /− podocytes and upregulates LEF1 in
CD2AP− /− podocytes (Supplementary Figure S5). Active
β-catenin binds to LEF1 to form transcription complexes to
activate target gene expression.31 In line with this, proximity
ligation assay (PLA) revealed that there is more interaction
between LEF1 and active β-catenin in CD2AP− /− podocytes
compared with WT podocytes (Figures 6c, d and g). XAV939
treatment decreased the prevalence of the interaction in
CD2AP− /− podocytes, possibly due to downregulation of
active β-catenin (Figures 6e–g). Taken together, the absence
of CD2AP leads to sustained activation of β-catenin in
podocytes, which upregulates LEF1. Interestingly, XAV939
treatment further upregulated LEF1 in CD2AP− /−
podocytes.
Tankyrase inhibition in CD2AP− /− podocytes aggra-
vates pro-apoptotic signaling and podocyte injury. Sev-
eral Wnt-signaling target genes, including Snail1,
plasminogen activator inhibitor-1 (PAI-1), fibroblast-specific
protein 1 (FSP-1), matrix metalloproteinase 9 (MMP-9) and
fibronectin, have been shown to be upregulated in kidney
injury.18,20 However, we observed no significant difference in
the expression levels of Snail1, PAI-1 and FSP-1 between
CD2AP− /− and WT podocytes (Figure 6h). Interestingly,
the absence of CD2AP significantly decreased the expres-
sion of MMP-9 (Figure 6h), and increased the expression of
fibronectin (Figures 6i and k). The data thus reveal regulation
of a specific set of Wnt-target genes in the absence
of CD2AP.
XAV939 treatment had no effect onMMP-9,Snail1 or FSP-1
expression in WTor CD2AP− /− podocytes (Figure 6h), and
fibronectin expression remained elevated in CD2AP− /−
podocytes (Figures 6i and k). Furthermore, XAV939 signifi-
cantly upregulated PAI-1 in CD2AP− /− podocytes
(Figure 6h). As also previously shown,8 the absence of
CD2AP increased the expression of apoptotic p38 MAPK
phosphorylation (Figures 6j and l). XAV939 treatment further
increased p38 MAPK phosphorylation (Figures 6j and l). Also
insulin-stimulated phosphorylation of anti-apoptotic AKT was
reduced by XAV939 treatment in podocytes lacking CD2AP
(Supplementary Figure S7). Additionally, we investigated the
expression of apoptotic markers in CD2AP− /− podocytes
with and without tankyrase inhibition. The absence of CD2AP
increased the expression of pro-apoptotic Bcl-2-associated X
protein (BAX) (Figures 6m and n), whereas the anti-apoptotic
B-cell lymphoma 2 protein (Bcl-2), a dual regulator of
apoptosis and autophagy, was downregulated. The autophagy
signaling adaptor protein p62 (sequestosome-1), which in a
context-dependent manner, has a role in the decision of the
cells undergoing autophagy to either survive or die, was
upregulated in the absence of CD2AP and XAV939 further
increased its expression (Figures 6m and n). Full-length
caspase-1 was downregulated in the absence of CD2AP
(Figures 6m and n). XAV939 treatment downregulated
full-length PARP1 in both WT and CD2AP− /− podocytes,
and increased the expression of cleaved, apoptotic form of
PARP1 in the absence of CD2AP (Figures 6m and n). The data
indicate that inhibition of tankyrases in the absence of CD2AP
aggravates podocyte injury by increasing pro-apoptotic
signaling and upregulating LEF1 and PAI-1 (see cartoon in
Figure 8).
Inhibition of tankyrases in cd2ap knockdown zebrafish
aggravates kidney injury. To analyze whether inhibition of
tankyrases increases podocyte injury in the absence of
CD2AP in vivo, we knocked down cd2ap with morpholino
antisense oligonucleotides (MOs) in zebrafish, previously
shown to result in pronephric kidney dysfunction,32 coupled
with tankyrase inhibition. At 5 days post fertilization (dpf),
60–68% of cd2ap-MO- and cd2ap-MO and tankyrase
inhibitor-treated larvae exhibited pericardial edema indicative
of kidney dysfunction (Figures 7a and b,Supplementary
Figure S6). Notably, simultaneous suppression of cd2ap
expression and tankyrase activity increased the number of
larvae displaying both pericardial and yolk sac edema from
13 to 27% (Figure 7d,Supplementary Figure S6) and
increased mortality from 3 to 17% compared with suppres-
sion of cd2ap expression alone (Figures 7b and d,
Supplementary Figure S6). Downregulation of cd2ap alone
or XAV939 treatment of control-MO-injected larvae had no
effect on viability (Supplementary Figure S6); and XAV939
treatment of control-MO-injected larvae caused no identifi-
able malformation (Figure 7c).
Control-MO-injected larvae without or with XAV939 treat-
ment showed well-developed glomeruli and pronephric ducts
(Figures 7e and g). The glomeruli of cd2ap-MO-treated larvae
exhibited disturbed glomerular structures with distended
capillary loops (Figure 7f), whereas the cd2ap knockdown
larvae treated with XAV939 showed even more disturbed
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Figure 5 Active β-catenin and its co-factors Lef1 and TCF-1 are upregulated in the absence of CD2AP. (a) Immunoblotting of wild-type (WT) and CD2AP− /− podocytes for
active β-catenin (ABC) in total lysates and nuclear fractions shows upregulation of active β-catenin. Tubulin and histone H3 (H3) are included as loading controls. (b and c)
Quantification of three replicate blots as in (a) indicates accumulation of active β-catenin in CD2AP− /− podocytes (b) and in the nuclei of CD2AP− /− podocytes (c). (d and e)
Immunofluorescence staining indicates that active β-catenin concentrates in the nucleus of CD2AP− /− podocytes. (f–k) Representative images of WT (f–h) and CD2AP− /−
(i–k) kidney sections labeled with active β-catenin (ABC) (f and i) and WT1 (g and j) IgGs. Merged images (h and k) show an increase in active β-catenin-positive podocytes
(arrows) in the absence of CD2AP (k). (l) Quantitative RT-PCR analysis indicates that Lef1 and TCF-1 are upregulated in CD2AP− /− podocytes compared with WT podocytes.
There is no difference in TCF-3 and TCF-4 expression. Tankyrase inhibitor XAV939 treatment of CD2AP− /− podocytes further upregulates Lef1 and TCF-1. Bars show the
mean and error bars the ±S.E.M. of three independent experiments. P-values were calculated with one-way ANOVA (*Po0.05; **Po0.01; ***Po0.001). Scale bar:
(d–k) 25 μm
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Figure 6 Tankyrase inhibitor treatment upregulates LEF1, fails to downregulate fibronectin and increases pro-apoptotic signaling in the absence of CD2AP.
(a) Immunoblotting of wild-type (WT) and CD2AP− /− podocyte lysates for active β-catenin (ABC), AXIN1 and LEF1 with or without tankyrase inhibitor XAV939 treatment.
Tubulin is included as a loading control. (b) Quantification of three replicate blots as in (a) indicates that tankyrase inhibitor treatment reduces active β-catenin and upregulates
AXIN1 in WTand CD2AP− /− podocytes. LEF1 is upregulated in CD2AP− /− podocytes and is further upregulated with tankyrase inhibitor treatment. (c–f) Representative
images of in situ proximity ligation assay (PLA) with ABC and LEF1 antibodies without (c and d) and with (e and f) tankyrase inhibitor XAV939 treatment. The red fluorescent dots
indicate interaction between ABC and LEF1. DAPI is used as a nuclear counterstain. (g) Quantification of three independent PLA experiments shows that there is more interaction
of active β-catenin and LEF1 in the CD2AP− /− podocytes compared with WT podocytes, and that this interaction is downregulated with tankyrase inhibitor treatment.
(h) Quantitative RT-PCR analysis indicates that MMP-9 is downregulated in CD2AP− /− podocytes compared with WT podocytes. The expression of PAI-1, Snail1 and
FSP-1 does not differ between the cell lines. XAV939 treatment of CD2AP− /− podocytes upregulates PAI-1, and has no significant effect on MMP-9, Snail1 and FSP-1 in
CD2AP− /− podocytes. (i) Immunoblotting for fibronectin in WTand CD2AP− /− podocytes treated or not with tankyrase inhibitor XAV929. (j) Immunoblotting with an antibody
against phosphorylated p38 MAPK (pp38 MAPK) in WT and CD2AP− /− podocytes treated or not with tankyrase inhibitor XAV939. (k) Quantification of three independent
blots as in (i) shows that fibronectin is upregulated in CD2AP− /− podocytes, and that tankyrase inhibitor treatment does not significantly downregulate its expression in
CD2AP− /− podocytes. (l) Quantification of three replicate blots as in (j) shows that phosphorylation of p38 MAPK is increased in the absence of CD2AP. Tankyrase inhibitor
further upregulates the phosphorylation of p38 MAPK in the absence of CD2AP, and also upregulates phosphorylation of p38 MAPK in WT podocytes. (m) Immunoblotting for
P62, BAX, Bcl-2, PARP1 and caspase-1 in WTand CD2AP− /− podocytes. Tubulin was used as a loading control. (n) Quantification of three replicate blots as in (m) shows the
effects of XAV939 treatment on the indicated proteins. Bars show the mean and error bars the ±S.E.M. of three independent experiments with three biological replicates.
P-values were calculated with one-way ANOVA (*Po0.05; **Po0.01; ***Po0.001). Scale bar: (c–f) 25 μm
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Figure 7 Simultaneous disruption of cd2ap expression and tankyrase activity aggravates kidney injury in zebrafish larvae. (a and b) Knockdown of cd2ap with morpholino
antisense oligonucleotides (cd2ap-MO) in zebrafish causes pericardial edema (arrowhead) at 5 days post fertilization (dpf) indicative of kidney dysfunction (b). Control-MO
(C-MO)-injected larvae appear developmentally normal (a). (c and d) Inhibition of tankyrase activity with XAV939 in the cd2ap morphant between 3 and 5 dpf induces yolk sac
edema and more severe pericardial edema (d, arrowhead) than knockdown of cd2ap alone (b), whereas XAV939 treatment has no effect on the control morphant (c). (e and g)
Histological sections of 5 dpf control morphant (e) and control morphant treated with XAV939 (g) show normal glomeruli (arrowheads) and proximal convoluted tubules (arrows).
(f) cd2ap morphant shows a disturbed glomerular structure (arrowhead) with cysts (asterisk). (h) Inhibition of tankyrase activity with XAV939 in cd2ap morphants leads to even
more destructed glomerular structure with a dilated (asterisk) and stretched septal glomerulus in the midline (arrowhead) and dilated proximal convoluted tubule (arrow).
(i) Immunoblotting for podocin and active β-catenin (ABC) in control morphants (C-MO) and cd2ap morphants (cd2ap-MO) with and without XAV939 treatment. α-Tubulin is
included as a control. (j) Quantification of three replicate blots as in (i) shows significant downregulation of podocin and upregulation of ABC in cd2ap morphants compared with
control morphants. XAV939 treatment further downregulates podocin in cd2ap morphants. (k) Knockdown of cd2ap with cd2ap-MO in zebrafish leads to an increase in total
PARylation at 5 dpf compared with control-MO treated zebrafish. P-values were calculated with one-way ANOVA (**Po0.01; ***Po0.001). Scale bar: (e–h) 25 μm
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glomerular structures with dilated Bowman's space and
proximal convoluted tubules and stretched, septal glomeruli
at the midline (Figure 7h) indicating severe kidney damage.
Suppression of cd2ap downregulated podocin (Figures 7i
and j), a protein essential for glomerular structure and
function.33 Notably, XAV939 treatment further downregulated
podocin in cd2ap-MO-injected larvae, but had no effect in
control-MO-injected larvae (Figures 7i and j). In line with the
in vitro experiments, active β-catenin was upregulated in
cd2ap-MO-injected larvae (Figures 7i and j). Additionally,
suppression of cd2ap increased total PAR levels compared
with controls (Figure 7k). Collectively, the data indicate that
suppression of cd2ap coupled with inhibition of tankyrases
leads to more severe kidney damage than knockdown of
cd2ap alone and increases mortality of the larvae.
Discussion
Canonical Wnt/β-catenin signaling mediates podocyte injury
and the development of proteinuria,18,20 and podocyte-
specific deletion of β-catenin protects from nephropathy.19,20
Tankyrases have been shown to be efficient targets in
inhibiting this signaling.17 Here, we show that CD2AP interacts
with tankyrase 1 and tankyrase 2, and that in the absence of
CD2AP tankyrase-mediated total PARylation in podocytes is
increased. Podocytes lacking CD2AP accumulate active
β-catenin consequently leading to upregulation of LEF1 and
fibronectin, both associated with podocyte injury. Tankyrase
inhibitor treatment reduces total PARylation and β-catenin
activation in cultured podocytes, but, surprisingly, worsens
kidney injury and increases mortality of zebrafish in the
absence of CD2AP.
Increased PARylation in podocytes has been shown to
have a role in glomerular injury associated with type 2 diabetes
and general PARP inhibitors ameliorate this pathological
situation.29 We found that tankyrases are phosporylated in
podocytes and that the absence of CD2AP leads to increased
total PARylation due to the activity of tankyrases. AutoPAR-
ylation of tankyrases was reduced in the absence of CD2AP,
indicating that PARylation of tankyrase binding partners or
unbound PAR would contribute to the overall increase
in total PAR. In line with this, PARP1 PARylation was found
modestly increased when CD2AP was depleted. The data
also indicated that CD2AP is not PARylated. Very little is still
known about the complex relationship between tankyrase
phosphorylation, autoPARylation and PARylation activity
and the data available on their relationship vary, apparently
reflecting cell-type and interaction partner-dependent
differences.14–16,23,26,27 Most of the known interaction
partners of tankyrases are acceptors of tankyrase
PARylation.14,15,23 CD2AP bears similarity with few proteins,
Fanconi anemia protein FANCD2 that controls genomic
integrity,34 and GDP-mannose-4,6-dehydratase (GMD) that
is required for fucose synthesis,35 which bind tankyrases and
inhibit their activity, but are not PARylated.
Our data indicate apparent dysregulation of the
Wnt/β-catenin pathway in the absence of CD2AP. In cells
deficient of CD2AP, active β-catenin is stabilized and
translocated to the nucleus. This is coupled with upregulation
of its downstream targets, LEF1 and fibronectin, whereas
several other typical Wnt/β-catenin target genes associated
with kidney injury were not affected. Notably, upregulation of
LEF1 and fibronectin occurred without exogenic Wnt stimula-
tion. Our data propose that the major enhancer of the
pathway is enhanced tankyrase PARylation activity (Figure 8,
CD2AP− /− ). Interestingly,MMP-9 was downregulated in the
absence of CD2AP. Lack of CD2AP predisposes cells to
apoptosis,8 and therefore reduced level of MMP-9, shown to
protect tubular cells against apoptosis in acute kidney injury,36
could contribute to the susceptibility of CD2AP-deficient
podocytes to apoptosis.
Inhibition of tankyrases has been shown to attenuate
pathological conditions associated with activation of Wnt
signaling, such as solid tumors37,38 and fibrotic pulmonary
diseases.39,40 On the basis of this, targeting theWnt/β-catenin
pathway could also serve as a therapeutic strategy to treat a
variety of proteinuric kidney diseases showing activation of the
Wnt pathway, as also Wang et al.18 suggested. We found that
treatment of CD2AP− /− podocytes with tankyrase inhibitor
reduced the activity of β-catenin. However, it did not
significantly reduce the increased expression of fibronectin,
further increased the expression of LEF1, upregulated PAI-1
(Figure 8, CD2AP− /−+tankyrase inhibitor), a fibrogenic
factor that has been associated with the development of
nephropathy,41 and increased pro-apoptotic signaling. Pre-
viously, it has been shown that upregulation of LEF1 coupled
with accumulation of active β-catenin renders cancer cells
unresponsive to tankyrase inhibition, which is due to LEF1
limiting the association of β-catenin with the destruction
complex.42 Tankyrase inhibition in these situations leads as
a forward regulatory loop to further upregulate LEF1. A
situation similar to this could explain our findings in podocytes
lacking CD2AP. Moreover, LEF1 and TCF-1 can be transcrip-
tionally active also independently of β-catenin,43 and as PAI-1
gene promoter harbors a functional TCF/LEF site,22 the
observed PAI-1 upregulation can be a result of LEF1 activating
the transcription of PAI-1. We thus propose a mechanism by
which tankyrase inhibition aggravates podocyte injury in the
absence of CD2AP: tankyrase inhibition leads to upregulation
of LEF1, which in turn enhances transcription of PAI-1
independently of β-catenin (Figure 8, CD2AP− /−+tankyrase
inhibition). These events contribute to the detrimental con-
sequences of tankyrase inhibition in the absence of CD2AP.
The harmful effects of inhibition of tankyrases in the
absence of CD2AP were further supported in zebrafish larvae
in vivo, in which knockdown of CD2AP coupled with inhibition
of tankyrases increased the severity kidney injury and
mortality. As both CD2AP and tankyrases are widely
expressed,2,44 may the phenotype reflect defects in the
function of multiple tissues. The worsening of the kidney
phenotype is a significant finding when considering treatment
strategies for kidney diseases associated with impairment of
CD2AP, such as FSGS.45,46 Mutations in CD2AP observed in
FSGS typically lead to reduced expression or absence of
CD2APor render CD2AP biologically defected.45,46 This could
lead to increased tankyrase activity in podocytes. Interestingly,
the Wnt pathway has been shown to be activated in patients
with primary or experimental FSGS,47 tempting to speculate
that Wnt inhibition would be a beneficial treatment strategy for
FSGS. Our findings, however, point out that inhibiting the Wnt
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pathway with tankyrase inhibitors in the absence of CD2AP
could be deleterious.
In summary, our data show a novel mechanism that
contributes to kidney injury and dysfunction in the absence
of CD2AP. We show that total PARylation and the activity of
β-catenin are elevated in CD2AP− /− podocytes, and that
both can be inhibited by tankyrase-specific small molecule
inhibitor. Tankyrase inhibition, however, further upregulates
proteins known to associate with kidney injury, and aggravates
kidney dysfunction and increases mortality in CD2AP-
depleted zebrafish larvae. These findings highlight that
inhibition of the Wnt/β-catenin pathway can have adverse
effects and that tankyrase inhibitors are not a suitable
approach to treat kidney diseases associated with lack
of CD2AP.
Materials and Methods
Yeast two-hybrid screening. Construction of the rat glomerular yeast two-
hybrid library and screening of the library using CD2AP as a bait have been
described previously.48,49
Animals. Male Sprague-Dawley rats and male FVB mice were used to study
tankyrases 1 and 2 expression in the kidney. Generation of CD2AP-knockout mouse
has been described.2 Kidneys of the knockout mice and controls were collected at
3 weeks of age and used for analyses as described below. Zebrafish embryos were
obtained from the breeding line of Turku strain and raised as described.50 Animal
experiments were performed according to approved guidelines and were approved
by the National Animal Experiment Board.
Cell culture, transient transfections and inhibitor treatments.
Conditionally immortalized podocytes derived from CD2AP− /− mice and WT
littermates8 and HEK293T cells were maintained in DMEM containing 4.5 g/l
glucose, 10% FCS, penicillin and streptomycin (Sigma-Aldrich, St. Louis, MO, USA).
Podocyte cultures were supplemented with 10 U/ml IFN-γ (Sigma-Aldrich).
HEK293T cells were transiently transfected with tankyrase 1 (kindly provided by
Dr. Susan Smith, New York University School of Medicine, New York, NY, USA),
flag-tagged tankyrase 2 and flag-tagged ankyrin domains of tankyrase 2 (kindly
provided by Dr. Nai-Wen Chi, University of California, San Diego, La Jolla, CA, USA)
using Lipofectamine 2000 (Invitrogen, Camarillo, CA, USA). Proliferating WT and
CD2AP− /− podocytes were cultured to 70% confluency and treated with 3 μM
XAV939 (Sigma-Aldrich), 3 μM ABT-888 (Selleckchem, Munich, Germany) or
DMSO for 18 h when indicated.
Antibodies. Antibodies used were rabbit anti-tankyrase 1/2 and mouse anti-
Bcl-2 (Santa Cruz Biotechnology, Dallas, TX, USA), rabbit anti-podocin and mouse
anti-tubulin (Sigma-Aldrich), goat anti-tankyrase 2, rabbit anti-BAX and rabbit anti-
fibronectin (Abcam, Cambridge, UK), rabbit anti-CD2AP 1774 or 1764,4,51 mouse
anti-PARP1 and rabbit anti-Poly(ADP-ribose) (Enzo Life Sciences, Farmingdale, NY,
USA), mouse anti-active-β-catenin (Millipore, Billerica, MA, USA), rabbit anti-LEF1
and rabbit anti-phospho p38 MAPK (Cell Signaling Technology, Danvers, MA,
USA) and mouse anti-WT1 (Upstate, Lake Placid, NY, USA), guinea pig
anti-p62/SQSTM1 (Progen Biotechnik GmbH, Heidelberg, Germany) and mouse
anti-Caspase-1 (Adipogen, San Diego, CA, USA).
Preparation of tissue and cell lysates and nuclear extracts.
Glomerular and tubular fractions were isolated from rat kidney cortices using graded
sieving.52 Tissues and cells were lysed as described.53 Pooled zebrafish larvae
were sonicated in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS supplemented with 1 mM PMSF and protease
inhibitor cocktail (Roche, Basel, Switzerland). Nuclear extracts were prepared as
described.35,54
Pull-down assay, immunoprecipitation and immunoblotting.
Pull-down assay with glutathione-S-transferase (GST)-tagged SH3 domains55 or
the NH2-terminus (amino acids 1–330) of mouse CD2AP was performed as
described.5 Pull-down assay for PARylated proteins was performed with a WWE
Affinity Resin kit (Tulip Biolabs, West Point, PA, USA) according to the
manufacturer's instructions, and immunoprecipitation as described.5 Immunoblotting
was performed as described.51
Figure 8 Schematic illustration of the molecular mechanisms contributing to injury of CD2AP-deficient podocytes upon tankyrase inhibition. In WT podocytes, CD2AP
interacts with tankyrases (TNKS) and inhibits their activity. In CD2AP− /− podocytes, the activity of tankyrases is increased, leading to inhibition of beta-catenin (BC)
degradation. Active beta-catenin (ABC) accumulates and translocates to the nucleus, where it together with LEF1 upregulates fibronectin. Tankyrase inhibition in CD2AP− /−
podocytes leads to accumulation of AXIN1 and degradation of active beta-catenin. However, tankyrase inhibition fails to downregulate fibronectin, further upregulates LEF1 and
enhances PAI-1 expression. Additionally, phosphorylation of the pro-apoptotic p38 MAPK is enhanced. These events further aggravate injury in CD2AP-deficient podocytes
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Immunoperoxidase staining. Mouse kidneys were fixed with 10% formalin,
dehydrated and embedded in paraffin. Immunoperoxidase staining was performed
with a VectaStain Elite kit (Vector Laboratories, Burlingame, CA, USA) as
described.49 Sections were analyzed with a Nikon Eclipse 800 microscope
(Nikon, Tokyo, Japan).
Immunofluorescence staining. Mouse kidney frozen sections (6 μm) were
fixed with acetone and cultured podocytes were fixed with 4% paraformaldehyde
(PFA) and permeabilized with 0.1% Triton X-100. The stainings were carried out as
described.53 AlexaFluor 594 donkey anti-rabbit and AlexaFluor 488 donkey anti-goat
or donkey anti-mouse IgGs were used as secondary antibodies. Samples were
analyzed with Leica TCS SP2 or SP8 confocal microscopes (Leica Microsystems,
Wetzlar, Germany).
PARylation assay. The total PARylation was measured with HT PARP in vivo
Pharmacodynamic Assay II (Trevigen, Gaithersburg, MD, USA).
Duolink in situ PLA. Duolink in situ PLA was carried out according to the
manufacturer’s instructions (Duolink, Olink Bioscience, Uppsala, Sweden).
Fluorescence images were captured using Zeiss Axioplan2 microscope (Carl Zeill
Microscopy, Thornwood, NY, USA). Quantification was performed using the Duolink
Image Tool (Olink Bioscience).
Quantitative RT-PCR. Quantitative PCR was performed as described in
Wang et al.56 Primer sequences for Snail1, MMP-9, FSP-1, PAI-1, LEF1, TCF-1,
TCF-3 and TCF-4 are shown in Supplementary Table S1. The expression levels of
the studied molecules were normalized to β-actin using the comparative Ct method.
Reverse transcriptions were performed with three individual RNA preparations and
quantitative RT-PCRs were performed in triplicate.
Knockdown and tankyrase inhibitor treatment in zebrafish. MO
blocking translation of cd2ap (5′-CATACTCCACCACCACCTCAACCAT-3′)32 and
a standard control MO were purchased from GeneTools, LLC (Philomath, OR,
USA). Zebrafish embryos were injected with 4 nl of 100 μM MOs using a Narishige
MN-153 microinjector (Tokyo, Japan). Embryos were allowed to develop until 3 days
post fertilization (dpf) and then transdermally exposed to 5 μM XAV939 or an
equivalent volume of DMSO (0.05%) in E3 medium for 2 days. The phenotype of
larvae on 5 dpf was examined under a Leica dissecting microscope.
Histology of zebrafish larvae. Zebrafish larvae at 5 dpf were fixed with 4%
PFA in PBS overnight at 4 °C and embedded in JB-4 (Polysciences, Inc., Warrington,
PA, USA). In all, 4 μm sections were stained with hematoxylin and eosin.
Statistical analysis. Statistical analysis was performed with one-way ANOVA.
Results are presented as mean± S.E.M.
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